Company intelligence / Profile preview

Ewopharma

Schaffhausen, Schaffhausen, Switzerland

Ownership: Private
Employees: ~424
Development stage: Other

Overview

Ewopharma commercializes a portfolio of prescription (Rx), OTC, and proprietary consumer health products in Central Eastern Europe and Switzerland, with marketed products such as Isoprinosine® (antiviral) and Revalid® (hair/skin consumer health)[3][4]. The company does not develop new molecular entities in-house but acquires, licenses, and markets products, showing a robust commercial presence and expansion through acquisition of Newport Pharmaceuticals, Neomed s.r.o., and AllergyCare Ltd[3][4].

Therapeutic areas: ImmunologyInfectious DiseasesDermatologyOncologyNeurology
Modalities: Small moleculeBiologicProteinPeptidesDevice
Industry: Consulting

Partnerships

Multiple in-licensing and commercialization partnerships with pharma and biotech companies (specific partners not consistently publicly disclosed)

Beyond the preview

Go deeper on Ewopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ewopharma.

Explore the full profile